Journal article
Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks
Circulation (New York, N.Y.), v 105(5), pp 589-594
05 Feb 2002
PMID: 11827924
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Implantable cardioverter defibrillator (ICD) use reduces mortality in patients with serious ventricular arrhythmias compared with antiarrhythmic drug (AAD) use. However, the relative impact of these therapies on self-perceived quality of life (QoL) is unknown.
Three self-administered instruments were used to measure generic and disease-specific QoL in Antiarrhythmics Versus Implantable Defibrillators trial participants. Generalized linear models were used to assess the relationships between self-perceived QoL and treatment (AAD versus ICD) and adverse symptoms and ICD shocks. To minimize the impact of missing data, only patients surviving 1 year were included in the primary analyses. Baseline characteristics among QoL participants (n=905) and nonparticipants (n=111) were similar, but participants who survived 1 year (n=800) were healthier at baseline than nonsurvivors (n=105). Of the 800 patients in the primary analysis, characteristics of those randomized to AAD (n=384) versus ICD (n=416) were similar. Overall, ICD and AAD use were associated with similar alterations in QoL. The development of sporadic shocks and adverse symptoms were each associated with reduced physical functioning and mental well-being and increased concerns among ICD recipients, whereas development of adverse symptoms was associated with reduced physical functioning and increased concerns among AAD recipients.
ICD and AAD therapy are associated with similar alterations in self-perceived QoL over 1-year follow-up. Adverse symptoms were associated with reduced self-perceived QoL in both groups, and sporadic shocks were associated with reduced QoL in ICD recipients.
Metrics
Details
- Title
- Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks
- Creators
- Eleanor B Schron - National Heart Lung and Blood InstituteDerek V Exner - Brigham and Women's HospitalQing Yao - Brigham and Women's HospitalLouise S Jenkins - Brigham and Women's HospitalJonathan S Steinberg - Brigham and Women's HospitalJames R Cook - Brigham and Women's HospitalSteven P Kutalek - Brigham and Women's HospitalPeter L Friedman - Brigham and Women's HospitalRosemary S Bubien - Brigham and Women's HospitalRichard L Page - Brigham and Women's HospitalJudy Powell - Brigham and Women's HospitalAVID InvestigatorsJacob R Powell - Chemistry
- Publication Details
- Circulation (New York, N.Y.), v 105(5), pp 589-594
- Grant note
- N01 HC-25117 / NHLBI NIH HHS
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- College of Medicine; Chemistry
- Web of Science ID
- WOS:000173735400025
- Scopus ID
- 2-s2.0-0037022208
- Other Identifier
- 991019169113004721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Cardiac & Cardiovascular Systems
- Peripheral Vascular Disease